CPC A61K 35/17 (2013.01) [A61K 47/65 (2017.08); C07K 14/4748 (2013.01); C07K 14/7051 (2013.01); C07K 16/2803 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01)] | 14 Claims |
1. A modified cell engineered to express an antigen binding molecule, wherein expression and/or function of CXCR3 in the modified cell has been enhanced, and wherein the modified cell comprises nucleic acid sequence SEQ ID NO: 125.
|